| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| P425290-1ml |
1ml |
现货  |
|
| 别名 | 3,7-二甲基-1-(5-氧代己基)黄嘌呤 | 3,7-二氢-3,7-二甲基-1-(5-氧代己基)-1H-嘌呤-2,6-二酮 | 1-(5-氧代己基)可可碱 |
|---|---|
| 英文别名 | pentoxifylline | Trental | 6493-05-6 | Oxpentifylline | Pentoxifyllin | Pentoxyphylline | Torental | Pentoxiphyllium | Vazofirin | Dimethyloxohexylxanthine | 3,7-Dimethyl-1-(5-oxohexyl)xanthine | Pentoxiphyllin | Pentoxiphylline | Pentoxyfylline | 1-(5-Oxohexyl)theobromine | Rentylin | |
| 规格或纯度 | Moligand™, 10mM in DMSO |
| 英文名称 | Pentoxifylline |
| 生化机理 | 磷酸二酯酶抑制剂。抑制TNF-α的合成。广谱细胞因子抑制剂。显示出抗炎和镇痛特性。 |
| 储存温度 | -80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 拮抗剂 |
| 作用机制 | 腺苷 A2 受体拮抗剂 |
| 产品介绍 |
Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor. Target: PDE Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNF and leukotriene synthesis, and reduces inflammation and innate immunity. In addition, pentoxifylline improves red blood cell deformability, reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation. Pentoxifylline is also an antagonist at adenosine 2 receptors . Pentoxifylline is generally well tolerated. Based on the totality of the available evidence, it is possible that pentoxifylline could have a place in the treatment of IC as a means of improving walking distance and as a complimentary treatment assuming all other essential measures such as lifestyle change, exercise and treatment for secondary prevention have been taken into account . Pentoxifylline reduce AST and ALT levels and may improve liver histological scores in patients with NALFD/NASH, but did not appear to affect cytokines. Large, prospective, and well-designed randomized, controlled studies are needed to address this issue . Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor. Target: PDE Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNF and leukotriene synthesis, and reduces inflammation and innate immunity. In addition, pentoxifylline improves red blood cell deformability, reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation. Pentoxifylline is also an antagonist at adenosine 2 receptors . Pentoxifylline is generally well tolerated. Based on the totality of the available evidence, it is possible that pentoxifylline could have a place in the treatment of IC as a means of improving walking distance and as a complimentary treatment assuming all other essential measures such as lifestyle change, exercise and treatment for secondary prevention have been taken into account . Pentoxifylline reduce AST and ALT levels and may improve liver histological scores in patients with NALFD/NASH, but did not appear to affect cytokines. Large, prospective, and well-designed randomized, controlled studies are needed to address this issue . |
| ALogP | 0.3 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione |
| INCHI | 1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3 |
| InChi Key | BYPFEZZEUUWMEJ-UHFFFAOYSA-N |
| Smiles | CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C |
| Isomeric SMILES | CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C |
| PubChem CID | 4740 |
| 分子量 | 278.31 |
| Reaxy-Rn | 558929 |
| 熔点 | 105 °C |
|---|---|
| 分子量 | 278.310 g/mol |
| XLogP3 | 0.300 |
| 氢键供体数Hydrogen Bond Donor Count | 0 |
| 氢键受体数Hydrogen Bond Acceptor Count | 4 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 278.138 Da |
| 单同位素质量Monoisotopic Mass | 278.138 Da |
| 拓扑极表面积Topological Polar Surface Area | 75.500 Ų |
| 重原子数Heavy Atom Count | 20 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 426.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 |
| 预防措施声明 |
P264: 处理后要彻底洗手。 P270: 使用本产品时，请勿进食、饮水或吸烟。 P330: 漱口 P301+P312: 如误吞咽：如感觉不适，呼叫急救中心/医生。 P501: 将内容物/容器处理到。。。 |
| RTECS | XH2475000 |
| Merck Index | 7136 |
首页
400-620-6333
